<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作为您在谷歌上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>RTW Biotech Opportunities Ltd (RTW.L) 周三指出，Galera Therapeutics, Inc. (GRTX) 已与私募投资公司 Obsidian Therapeutics Inc. 签署了合并的最终协议，进行反向合并交易。</p>
<p>此次全股票合并将与一项 3.5 亿美元的私募融资同时进行，RTW Biotech Opportunities 参与其中。</p>
<p>合并后的公司预计将在 2026 年第三季度以 &#34;OBX &#34;的股票代码在纳斯达克上市交易。</p>
<p>Obsidian 是一家专注于实体肿瘤细胞疗法的临床阶段生物制药公司，正在推进其主要候选药物 OBX-115，进行针对晚期黑色素瘤的二期临床试验和针对非小细胞肺癌的一期临床试验。</p>
<p>截至 2026 年 3 月 31 日，Obsidian 约占 RTW Biotech Opportunities 净资产价值的 0.3%。</p>
<p>周二，RTW Biotech Opportunities 在伦敦证券交易所收盘上涨 3.38%，报 2.1400 美元。</p>
<p>周二，Galera Therapeutics 在场外交易市场收盘上涨 88.10%，报 0.0790 美元。</p>
<p>如有意见和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

GRTX

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

<p>RTW 生物科技机会有限公司宣布，Galera Therapeutics 将与 Obsidian Therapeutics 进行反向合并。这笔全股票交易包括 3.5 亿美元的私募融资。新实体将在 2026 年第三季度以 “OBX” 的股票代码在纳斯达克交易。Obsidian 专注于针对实体肿瘤的细胞疗法，其主要候选药物 OBX-115 正在进行黑色素瘤的二期试验和肺癌的一期试验。RTW 的股价上涨 3.38%，至 2.14 美元，而 Galera 的股价飙升 88.10%，至 0.0790 美元</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作为您在谷歌上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>RTW Biotech Opportunities Ltd (RTW.L), on Wednesday, noted that Galera Therapeutics, Inc. (GRTX) has entered into a definitive agreement to merge with private portfolio company Obsidian Therapeutics Inc. in a reverse merger transaction.</p>
<div class="lb-trans"><p>RTW Biotech Opportunities Ltd (RTW.L) 周三指出，Galera Therapeutics, Inc. (GRTX) 已与私募投资公司 Obsidian Therapeutics Inc. 签署了合并的最终协议，进行反向合并交易。</p>
</div><p>The all-stock merger will be conducted alongside a $350 million private placement financing, in which RTW Biotech Opportunities is participating.</p>
<div class="lb-trans"><p>此次全股票合并将与一项 3.5 亿美元的私募融资同时进行，RTW Biotech Opportunities 参与其中。</p>
</div><p>The combined company is expected to begin trading on the Nasdaq under the ticker &#34;OBX&#34; in the third quarter of 2026.</p>
<div class="lb-trans"><p>合并后的公司预计将在 2026 年第三季度以 &#34;OBX &#34;的股票代码在纳斯达克上市交易。</p>
</div><p>Obsidian, a clinical-stage biopharmaceutical company focused on cell therapies for solid tumors, is advancing its lead candidate OBX-115 in Phase 2 trials for advanced melanoma and Phase 1 trials for non-small cell lung cancer.</p>
<div class="lb-trans"><p>Obsidian 是一家专注于实体肿瘤细胞疗法的临床阶段生物制药公司，正在推进其主要候选药物 OBX-115，进行针对晚期黑色素瘤的二期临床试验和针对非小细胞肺癌的一期临床试验。</p>
</div><p>As of March 31, 2026, Obsidian represented approximately 0.3% of RTW Biotech Opportunities' net asset value.</p>
<div class="lb-trans"><p>截至 2026 年 3 月 31 日，Obsidian 约占 RTW Biotech Opportunities 净资产价值的 0.3%。</p>
</div><p>On Tuesday, RTW Biotech Opportunities closed trading 3.38% higher at $2.1400 on the London Stock Exchange.</p>
<div class="lb-trans"><p>周二，RTW Biotech Opportunities 在伦敦证券交易所收盘上涨 3.38%，报 2.1400 美元。</p>
</div><p>On Tuesday, Galera Therapeutics closed trading 88.10% higher at $0.0790 on the OTC.</p>
<div class="lb-trans"><p>周二，Galera Therapeutics 在场外交易市场收盘上涨 88.10%，报 0.0790 美元。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意见和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

黑曜石治疗公司将通过反向合并与 Galera Therapeutics 合并